EUDAWHIGH SIGNALFINANCIAL10-K

EUDAW experienced a dramatic balance sheet contraction with total assets declining over 70% while operating cash burn worsened substantially.

The massive reduction in current assets from $86.8M to $25.0M suggests either a major capital deployment, asset divestiture, or cash consumption that fundamentally altered the company's financial profile. The simultaneous deterioration in operating cash flow indicates the company is burning through resources at an accelerated pace, raising questions about capital allocation and operational sustainability.

Comparing 2023-06-28 vs 2022-08-29View on EDGAR →
FINANCIAL ANALYSIS

EUDAW's financials reflect a company in transition with concerning capital dynamics. While gross profit declined modestly to $3.4M and R&D expenses were substantially reduced, the most striking change was the dramatic shrinkage of the balance sheet with total assets falling from $86.8M to $25.6M. Operating cash flow deteriorated meaningfully, suggesting the company is consuming capital at a faster rate despite cost-cutting measures, creating potential liquidity concerns going forward.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-86.7%
$129K$17K

R&D spending cut 86.7% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-71.2%
$86.8M$25.0M

Current assets declined 71.2% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-70.5%
$86.8M$25.6M

Total assets contracted 70.5% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
-51.7%
-$1.0M-$1.5M

Operating cash flow fell 51.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-26.1%
$194K$143K

Cash decreased 26.1% — monitor burn rate and upcoming capital needs.

Gross Profit
P&L
-21%
$4.2M$3.4M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2023-06-28
PRIOR — 2022-08-29
ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
As of June 19, 2023, there were 24,777,509 ordinary shares outstanding.
Frequently used terms Unless otherwise stated in this Annual Report on Form 10-K ( Annual Report or Form 10-K ), or the context otherwise requires, references to we, us, our EUDA or the Company are to EUDA Health Holdings Limited, a British Virgin Islands exempt company and references to: 8i means 8i Acquisition 2 Corp., a BVI business company that changed its name to EUDA Health Holdings Limited after the Business Combination.
Board means the board of directors of 8i prior to the Closing, and the board of directors of the Company following the Closing.
Business Combination means the transactions contemplated under the SPA relating to the Share Purchase.
+7 more — sign up free →
REMOVED
As of August 29, 2022, 11,073,500 ordinary shares, no par value, were issued and outstanding.
The statements contained in this report that are not purely historical are forward-looking statements.
Our forward-looking statements include, but are not limited to, statements regarding our or our management s expectations, hopes, beliefs, intentions or strategies regarding the future.
In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
The words anticipates, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →